Sharma East India Hospitals & Medical Research Limited has notified BSE of an upcoming board meeting scheduled for Saturday, May 30, 2026, at its registered office located at Jaipur Hospital, Near SMS Stadium, Lal Kothi, Tonk Road, Jaipur. The intimation has been filed under Regulation 29 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.

Board Meeting Agenda

The board meeting has been convened to transact the following key business:

• Consideration and approval of the Standalone Audited Financial Results along with the Auditor Report for the year ended March 31, 2026, pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015.
• Any other business with the permission of the Chair and with the consent of a majority of Directors present, including at least one Independent Director.

The key details of the scheduled meeting are summarised below:

Trading Window Closure

In accordance with the Company's Code of Conduct to Regulate, Monitor and Report Trading by Insiders, the trading window for dealing in the securities of Sharma East India Hospitals & Medical Research Limited has been closed for Designated Persons and their immediate relatives. As communicated by the Company vide its letter dated March 27, 2026, the trading window closure is effective from Wednesday, April 01, 2026, and will remain closed until 48 hours after the declaration of the financial results and their availability as generally available information.

The intimation was signed by Bhawana Sharma, Company Secretary and Compliance Officer (M. No. A61665), on May 15, 2026, from Jaipur.

Sharmeh has announced its quarterly financial results for the third quarter of fiscal year 2026, marking another milestone in the company's regulatory compliance and transparency efforts. The healthcare services provider released its unaudited standalone financial results for the quarter ended December 31, 2025, following comprehensive board review and approval.

Board Meeting and Approval Process

The company's Board of Directors convened on February 14, 2026, at the registered office located at Jaipur Hospital, Near SMS Stadium, Lal Kothi, Tonk Road, Jaipur. The meeting details and outcomes are summarized below:

The board meeting was conducted in accordance with regulatory requirements, with Company Secretary and Compliance Officer Bhawana Sharma (Membership No. A61665) overseeing the compliance aspects of the announcement.

Regulatory Compliance and Standards

The financial results have been prepared in strict adherence to Indian Accounting Standards (Ind AS) as specified under Section 133 of the Companies Act, 2013. The company has ensured compliance with Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, including all relevant amendments and circulars issued by SEBI.

Key compliance highlights include:

• IND-AS compliant standalone unaudited financial results
• Limited review conducted by statutory auditors
• Audit Committee review and board approval
• Timely submission to BSE Limited (Scrip Code: 524548)

Independent Auditor Review

Gopal Sharma & Co., Chartered Accountants, conducted an independent limited review of the quarterly financial results. Partner CA Abhishek Sharma (Membership No. 079224) signed off on the review report dated February 14, 2026. The auditing firm, with registration number 002803C, confirmed that the financial statements comply with Indian Accounting Standards and disclosure requirements.

Corporate Structure and Communication

Sharma East India Hospitals & Medical Research Limited operates with its registered office in Jaipur, Rajasthan, and maintains active communication channels for stakeholders. The company's CIN is L85110RJ1989PLC005206, reflecting its incorporation in 1989 under the hospital and medical research sector classification.

The company has made the quarterly results announcement available on its official website at www.jaipurhospital.co.in , ensuring transparent access to financial information for all stakeholders. The organization continues to maintain its commitment to regulatory compliance and timely disclosure of material information to the stock exchanges and investors.